Stock Movers: Delta, L3Harris, Travere

Stock Movers

On this episode of Stock Movers:
- Delta Air Lines (DAL) is ordering 30 Boeing Co. 787 Dreamliner jets in its first-ever purchase of that model, providing a boost to the US planemaker that highlights the airline’s optimism for international travel demand.The announcement came as Atlanta-based Delta reported earnings for the fourth quarter that beat analyst estimates. Revenue last year rose to a record $58.3 billion, in line with analysts’ expectations, it said on Tuesday
- L3Harris (LHX) shares gain after the contractor said the Department of Defense is set to invest in its Missile Solutions business through a $1 billion convertible preferred security, which would automatically convert into common equity upon the unit’s planned IPO.
- Travere Therapeutics (TVTX) slumps after the biotech firm said it received a request from the FDA to clarify the clinical benefit of its therapy that treats a rare kidney disease, a move that analysts said could delay the approval by the agency.

See omnystudio.com/listener for privacy information.

More description

On this episode of Stock Movers:
- Delta Air Lines (DAL) is ordering 30 Boeing Co. 787 Dreamliner jets in its first-ever purchase of that model, providing a boost to the US planemaker that highlights the airline’s optimism for international travel demand.The announcement came as Atlanta-based Delta reported earnings for the fourth quarter that beat analyst estimates. Revenue last year rose to a record $58.3 billion, in line with analysts’ expectations, it said on Tuesday
- L3Harris (LHX) shares gain after the contractor said the Department of Defense is set to invest in its Missile Solutions business through a $1 billion convertible preferred security, which would automatically convert into common equity upon the unit’s planned IPO.
- Travere Therapeutics (TVTX) slumps after the biotech firm said it received a request from the FDA to clarify the clinical benefit of its therapy that treats a rare kidney disease, a move that analysts said could delay the approval by the agency.

See omnystudio.com/listener for privacy information.

2026-01-13 2 min Transcript
Listen elsewhere

Available Results

Generated results are saved to your library for reuse and search.

No generated results are available for this episode yet.

Transcript

Open the Transcript tab to load the transcript.

Chapters

No chapters available.